Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | QPCT | Q16769 | 1/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17093844 | 0.93 | CYP24A1 (0.33) | L3MBTL1MEN1KMT2AQPCTTBXAS1 | |
| SCHEMBL17372738 | 0.83 | L3MBTL1 (0.35) | L3MBTL1QPCTALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL15220075 | 0.81 | P2RX4 (0.44) | L3MBTL1POLB | |
| SCHEMBL9971314 | 0.80 | ALDH1A1 (0.43) | L3MBTL1MEN1KMT2AQPCTALDH1A1 | |
| SCHEMBL15212788 | 0.77 | TSHR (0.39) | L3MBTL1MEN1KMT2AQPCTALDH1A1 | |
| SCHEMBL31458633 | 0.77 | CA14 (0.39) | L3MBTL1MEN1KMT2AQPCTALDH1A1 | |
| SCHEMBL4014682 | 0.77 | MLLT1 (0.41) | L3MBTL1MEN1KMT2ATBXAS1ALDH1A1 | |
| SCHEMBL4256419 | 0.76 | QPCT (0.43) | L3MBTL1MEN1KMT2AQPCTLMNA | |
| SCHEMBL17209724 | 0.76 | L3MBTL1 (0.40) | L3MBTL1MEN1KMT2AALDH1A1CYP19A1 | |
| SCHEMBL30880341 | 0.75 | NAAA (0.45) | QPCTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150266867-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | NOVARTIS AG (CH) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266867-A1 | MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MGAM, MGAM2, BPGM | L3MBTL1 788/4885MEN1 1714/4885KMT2A 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.